Ajmaline

Revision as of 13:14, 29 April 2009 by Apalmer (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Ajmaline
Clinical data
ATC code
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC20H26N2O2
Molar mass326.433 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Ajmaline is a class Ia antiarrhythmic agent. It is often used to Bring out typical findings of ST elevations in patients suspected of having Brugada syndrome.

The compound was first isolated by Salimuzzaman Siddiqui in 1931 [1] from the roots of Rauwolfia serpentina. He named it Ajmaline, after Hakim Ajmal Khan, one of the most illustrious practitioners of Unani system of medicine in South Asia.[2]

Notes

  1. Siddiqui, S. & Siddiqui, R.H. (1931). Journal of the Indian Chemical Society, vol. 8, pp. 667-680.
  2. Ahmed Nasim Sandilvi (2003), Salimuzzaman Siddiqui: pioneer of scientific research in Pakistan. Daily Dawn. 12 April, 2003. Retrieved on 19 July, 2007.


Template:Antiarrhythmic agents

Template:SIB

de:Ajmalin


Template:WikiDoc Sources